Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement.
As measured, adherence to erenumab was high within the cohort. The inclusion of a work outcomes cohort provided valuable insights about the clinical benefits of erenumab for migraine prevention. Our findings provide additional insights on the real-world use of erenumab within the context of an outcomes-based agreement.
Authors
- Chester B. Good (ORCID: https://orcid.org/0000-0003-4388-4558)
- Elizabeth C.S. Swart (ORCID: https://orcid.org/0000-0002-8938-4236)
- Samuel K. Peasah (ORCID: https://orcid.org/0000-0002-4991-7392)
- Chronis Manolis (ORCID: https://orcid.org/0000-0002-3594-4779)
- Yan Huang (ORCID: https://orcid.org/0000-0003-1043-7604)
- Mark Bensink (ORCID: https://orcid.org/0000-0002-5940-7898)
- Melissa S Greco
Institutions
- University of Pittsburgh (US)
- UPMC Center for High Value Health Care (US)
Publication Details
- Journal
- PubMed
- Published
- 2025-03-01
- DOI
- https://doi.org/10.18553/jmcp.2025.31.3.236
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00